MODERNA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 140 USD | -3.58% |
|
-9.48% | +40.80% |
| Jun. 14 | FDA asks COVID vaccine makers to target KP.2 strain with updated shots | RE |
| Jun. 13 | Moderna: successful trial for new Covid vaccine | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Calendar
2024-07-31
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
145.2
USD
Average target price
145.2
USD
Spread / Average Target
-0.04%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +40.80% | 55.66B | |
| -8.05% | 38.98B | |
| +35.79% | 38.8B | |
| -8.98% | 27.32B | |
| +10.69% | 26.29B | |
| -16.21% | 20.25B | |
| +31.00% | 12.76B | |
| +28.51% | 12.18B | |
| -1.67% | 12.12B | |
| -11.39% | 10.94B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Sector Update: Health Care Stocks Slipping Late Afternoon
